Birch Pollen Allergy Clinical Trial
Official title:
Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure
It is an open-label physiological investigation of the allergic skin reactivity to epicutaneous allergen exposition in 20 allergic patients in two different skin conditions. The focus of the study is on the skin preparation/condition and not on the specific allergen or allergy, but for reasons of homogeneity a single allergic disease, birch pollen allergy was chosen as the basis for the testing. In order to evaluate the effects of the two different skin preparation techniques an intraindividual comparison of the skin reactivity in terms of the immediate phase I reaction to serial dilutions of birch pollen extracts was chosen. The serial dilution approach allows a dose dependent effect evaluation and comparison of the sensitivity. The differences will be explained mainly by the two different skin preparations allowing a quantitative comparison of these techniques.
The Objective is the determination of the allergic skin reactivity to epicutaneoulsy applied
birch pollen allergen extract after skin preparation (microporation by P.L.E.A.S.E.
Professional) and standard skin prick test. By using the standard prick test the stratum
corneum is overcome by a single puncture (1 mm).
Micropores induced by P.L.E.A.S.E. Professional penetrate the stratum corneum less deep but
with a higher density (five pores). It is therefore suggested that a skin preparation with
micropores by P.L.E.A.S.E. Professional previously to the allergen contact may lead to a
higher sensitivity. Less allergen might still elicit a skin reaction which won?t be seen by
a conventional prick skin test. Whereas skin prick test may lead to true-negative (patient
shows no allergic reaction on prick skin test but is an allergy sufferer in clinic),
IgE-determination may lead to false-positives (patient is determined as allergy sufferer but
has no clinical symptoms). So the sensitivity with micropores skin preparation by
P.L.E.A.S.E. Professional could be a good compromise. The preparation of the skin with
P.L.E.A.S.E. Professional leads to a better understanding of the influence of different
types of skin injury patterns on the allergic skin reactivity. Namely, how important is the
role of the exposed area, the depth of injury and the keratinocyte activation.
This will be checked in a late phase reaction evaluation.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06037148 -
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
|
Phase 1 | |
Completed |
NCT04912076 -
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
|
Phase 1 | |
Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
Completed |
NCT01137357 -
Probiotics for Reduction Of Markers In Subjects With Allergy
|
N/A | |
Active, not recruiting |
NCT05668390 -
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
|
Phase 3 | |
Not yet recruiting |
NCT02146300 -
Effect of the Nasal Provocation on the Breathing Style
|
N/A | |
Completed |
NCT01449786 -
Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy
|
Phase 2 | |
Completed |
NCT03969849 -
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
Completed |
NCT01628484 -
Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation
|
Phase 1 | |
Completed |
NCT00932607 -
SUBLIVAC® Birch PROBE Study
|
Phase 2 | |
Completed |
NCT00266526 -
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
|
Phase 2 | |
Completed |
NCT02143583 -
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
|
Phase 2 | |
Completed |
NCT04266028 -
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
|
Phase 1 | |
Completed |
NCT00309062 -
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT01675791 -
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
|
Phase 2 |